Dexloxiglumide: Rotta research lab

Current Opinion in Investigational Drugs

Volumn 3, Issue 4, 2002, Pages 621-626

  Varga, Gábor ^a  

^a INSTITUTE OF EXPERIMENTAL MEDICINE   (Hungary)

Author keywords

[No Author keywords available]

Indexed keywords

CAMOSTAT; CHOLECYSTOKININ RECEPTOR BLOCKING AGENT; DEXLOXIGLUMIDE; LOXIGLUMIDE; CHOLECYSTOKININ RECEPTOR; VALERIC ACID DERIVATIVE;

CLINICAL TRIAL; DRUG MARKETING; DRUG METABOLISM; DRUG SYNTHESIS; DRUG TOLERABILITY; GALLBLADDER CONTRACTION; GASTROINTESTINAL DISEASE; GASTROINTESTINAL MOTILITY; GASTROINTESTINAL SYMPTOM; GASTROINTESTINAL TRANSIT; HUMAN; IRRITABLE COLON; LOWER ESOPHAGUS SPHINCTER PRESSURE; MALAISE; NONHUMAN; PANCREAS TUMOR; PANCREATITIS; RACEMIC MIXTURE; REVIEW; STOMACH EMPTYING; STRUCTURE ACTIVITY RELATION; TOXICITY TESTING; ANIMAL; DIGESTIVE FUNCTION; DRUG ANTAGONISM; DRUG EFFECT; DYSPEPSIA; GALLBLADDER EMPTYING; METABOLISM;

ANIMAL; CLINICAL TRIALS; COLONIC DISEASES, FUNCTIONAL; DYSPEPSIA; GALLBLADDER EMPTYING; GASTROINTESTINAL SYSTEM; HUMAN; PENTANOIC ACIDS; RECEPTORS, CHOLECYSTOKININ; ANIMALS; DIGESTIVE PHYSIOLOGY; HUMANS;

EID: 0035988866     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (46)

1. Effect of CCK and its antagonists on gastric emptying
2. CCK-A antagonists: Which and how
3. A cholecystokinin receptor antagonist, loxiglumide, stimulates biliary secretion in conscious rats
4. Effect of dexloxiglumide and spiroglumide, two new CCK-receptor antagonists, on gastric emptying and secretion in the rat: Evaluation of their receptor selectivity in vivo
5. Drug development pipeline: Nebostinel, dexloxiglumide, CR-2991, CR-2345, itriglumide and CR-2471/P
6. Cholecystokinin-A receptor antagonists: Therapies for gastrointestinal disorders
7. Effect of a CCK-A receptor antagonist in an experimental model of delayed colonic transit time in man
8. A receptor blockade
9. Management of irritable bowel syndrome: Novel approaches to the pharmacology of gut motility
10. A) receptor antagonist, treatment of irritable bowel syndrome
11. CCK-A receptor blockade improves dyspeptic symptoms due to duodenal lipid and gastric distension in functional dyspepsia
12. The CCK-A receptor-antagonist dexloxiglumide in the treatment of IBS
13. International Union of Pharmacology. XXI. Structure, distribution, and functions of cholecystokinin receptors
14. The CCK1 receptor antagonist dexloxiglumide does not increase the risk of gallstone formation
15. Forest Laboratories announces agreement with Rotta Research for license of dexloxiglumide
16. Global Healthcare Bulletin
17. Pharmaceuticals: Speciality pharmaceuticals model and pipeline book: 2nd (June) Quarter 2000 Issue
18. Forest Laboratories Inc.
19. Drug development pipeline; CR-3465, CR-3124 and CR-3294
20. Specialty Pharmaceuticals - Specialty pharmaceutical model and pipeline book: 1st quarter 2001 issue
21. European Association of Clinical Pharmacology and Therapeutics - Fifth Congress (Part II) - Overnight Report, Odense, Denmark
22. US Specialty Pharmaceuticals: Monthly dose
23. Role of duodenal lipid and cholecystokinin A receptors in the pathophysiology of functional dyspepsia
24. Biological actions of cholecystokinin
25. The human brain cholecystokinin-B/gastrin receptor. Cloning and characterization
26. Cholecystokinin suppresses food intake by a nonendocrine mechanism in rats
27. Effect of three nonpeptide cholecystokinin antagonists on human isolated gall bladder
28. Inhibitory action of dexloxiglumide on transient lower oesophageal sphincter relaxations in dogs
29. Effects of dexloxiglumide on gastric emptying delayed by colonic distension in dogs
30. Pharmacological and molecular characterization of muscular cholecystokinin receptors in the human lower oesophageal sphincter
31. Effect of lintitript, a new CCK-A receptor antagonist, on gastric emptying of a solid-liquid meal in humans
32. Effects of dexloxiglumide on CYP450 isozymes in human liver microsomes
33. Pharmacokinetics of dexloxiglumide after single and repeat oral escalating doses in healthy volunteers
34. Interaction of dexloxiglumide (CR2017) with human liver cytochromes P450
35. Phase I metabolism of dexloxiglumide (CR2017) by human liver microsomes
36. Effect of the CCK-A receptor antagonist dexloxiglumide on post-prandial gallbladder emptying and colonic transit time in healthy volunteers
37. Effect of the CCK-A receptor antagonist dexloxiglumide on post-prandial gallbladder emptying and colonic transit time in healthy volunteers
38. The efficacy and safety of the CCK-A receptor-antagonist dexloxiglumide in the treatment of IBS
39. The CCK-1 receptor antagonist dexloxiglumide is effective and safe in female patients with constipation predominant irritable bowel syndrome
40. The CCK-1 receptor antagonist dexloxiglumide does not increase the risk of gallstone formation
41. Identification of an irreversible cholecystokinin (CCK) receptor antagonist
42. Review: Pathogenesis of gallstones
43. Mechanism for the transit-induced increase in colonic deoxycholic acid formation in cholesterol cholelithiasis
44. Cholecystokinin antagonists and motilides: Pharmacology and potential in the treatment of gastroesophageal reflux disease and other digestive motor disorders
45. Influence of dexloxiglumide on visceromotor and pain response induced by rectal distension in rats
46. Endogenous cholecystokinin modulates tolerance to an intragastric liquid load via an effect on gastric emptying in humans